ImmunoCellular Therapeutics (IMUC) Misses Q4 EPS by 16c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c